EP
FLGT icon

Essential Partners’s Fulgent Genetics FLGT Stock Holding History

Essential Partners’s Portfolio FLGT Stock Details FLGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.76K Hold
80
– – ﹤0.01% 1967
2026
Q2 		$1.64K Sell
80
-9
-10% -$153 ﹤0.01% 2056
2026
Q1 		$1.42K Buy
+89
New +$1.93K ﹤0.01% 2126

Other funds holding FLGT

HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
ATC
Adirondack Trust Company Saratoga Springs, New York $320M AUM 23.25% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
FFO
Fortitude Family Office Scottsdale, Arizona $586M AUM 20.58% 1-Year Est. Return
CoreCap Advisors
CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return
TCM
Triumph Capital Management Denver, Colorado $573M AUM 15.32% 1-Year Est. Return

Essential Partners's FLGT Position: Q3 2026 in Review

Essential Partners held its Fulgent Genetics (FLGT) position steady in Q3 2026 at 80 shares worth $1.76K. The position accounts for ﹤0.01% of the portfolio, ranked #1967.

Essential Partners first reported a position in FLGT in Q1 2026 and has held it in 3 quarters since. 10 funds tracked by Wall St. Rank hold FLGT as of Q3 2026.

  • Essential Partners held 80 shares of Fulgent Genetics worth $1.76K as of Q3 2026.
  • Essential Partners left its Fulgent Genetics share count unchanged in Q3 2026.
  • Fulgent Genetics made up ﹤0.01% of Essential Partners's portfolio in Q3 2026, its #1967 holding.
  • Essential Partners first reported a position in Fulgent Genetics in Q1 2026 and has held it in 3 quarters since.
  • 10 funds tracked by Wall St. Rank held Fulgent Genetics as of Q3 2026.

Based on Essential Partners's 13F filing for Q3 2026, filed 14 Oct 2026.